Privium Fund Management B.V. Purchases 2,900 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Privium Fund Management B.V. grew its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 45.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 9,250 shares of the company's stock after acquiring an additional 2,900 shares during the quarter. Krystal Biotech comprises about 0.3% of Privium Fund Management B.V.'s holdings, making the stock its 29th largest position. Privium Fund Management B.V.'s holdings in Krystal Biotech were worth $1,449,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Oppenheimer Asset Management Inc. bought a new position in Krystal Biotech during the third quarter worth $235,000. KBC Group NV increased its holdings in shares of Krystal Biotech by 25.9% during the third quarter. KBC Group NV now owns 642 shares of the company's stock valued at $117,000 after purchasing an additional 132 shares during the period. Swiss National Bank grew its holdings in Krystal Biotech by 8.0% during the third quarter. Swiss National Bank now owns 39,100 shares of the company's stock worth $7,117,000 after acquiring an additional 2,900 shares during the period. Quest Partners LLC grew its holdings in Krystal Biotech by 264.1% during the third quarter. Quest Partners LLC now owns 1,398 shares of the company's stock worth $254,000 after acquiring an additional 1,014 shares during the period. Finally, Segall Bryant & Hamill LLC grew its holdings in Krystal Biotech by 352.4% during the third quarter. Segall Bryant & Hamill LLC now owns 157,144 shares of the company's stock worth $28,605,000 after acquiring an additional 122,407 shares during the period. Institutional investors and hedge funds own 86.29% of the company's stock.

Remove Ads

Analysts Set New Price Targets

Several brokerages have recently issued reports on KRYS. HC Wainwright reiterated a "buy" rating and set a $221.00 price target on shares of Krystal Biotech in a report on Friday, February 28th. Chardan Capital boosted their price target on Krystal Biotech from $212.00 to $218.00 and gave the company a "buy" rating in a research note on Thursday, February 20th. Jefferies Financial Group assumed coverage on Krystal Biotech in a research note on Wednesday, March 5th. They issued a "buy" rating and a $245.00 price objective on the stock. Citigroup raised their price target on Krystal Biotech from $206.00 to $215.00 and gave the company a "neutral" rating in a report on Thursday, February 20th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $215.00 price target on shares of Krystal Biotech in a report on Thursday, February 20th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Krystal Biotech has an average rating of "Buy" and a consensus price target of $220.00.

Insider Transactions at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the firm's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the transaction, the insider now directly owns 1,463,711 shares in the company, valued at $260,233,178.69. This trade represents a 1.68 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CAO Kathryn Romano sold 750 shares of Krystal Biotech stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total value of $131,415.00. Following the transaction, the chief accounting officer now owns 12,604 shares of the company's stock, valued at $2,208,472.88. This represents a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 14.10% of the stock is currently owned by insiders.

Krystal Biotech Stock Performance

NASDAQ:KRYS traded down $0.57 during mid-day trading on Thursday, hitting $188.61. The company had a trading volume of 151,595 shares, compared to its average volume of 283,752. The firm has a market cap of $5.43 billion, a P/E ratio of 63.08 and a beta of 0.87. The business's fifty day moving average is $165.34 and its two-hundred day moving average is $173.69. Krystal Biotech, Inc. has a fifty-two week low of $141.72 and a fifty-two week high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings results on Monday, February 24th. The company reported $1.52 EPS for the quarter, topping analysts' consensus estimates of $1.29 by $0.23. The company had revenue of $91.10 million for the quarter, compared to analyst estimates of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. Krystal Biotech's revenue was up 116.4% compared to the same quarter last year. During the same quarter last year, the firm posted $0.30 earnings per share. Equities analysts forecast that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).